Nonalcoholic Steatohepatitis Therapeutics Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
steatohepatitis (NASH) can occur. It is the most extreme form of<br />
non-alcoholic fatty liver disease and is a direct causative factor<br />
for liver cirrhosis.<br />
Browse Full Research Report on <strong>Nonalcoholic</strong><br />
<strong>Steatohepatitis</strong> <strong>Therapeutics</strong> <strong>Market</strong>:<br />
http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html<br />
NAFLD by itself can be treated successfully if detected in time.<br />
NASH, on the other hand, needs special care. The global nonalcoholic<br />
steatohepatitis therapeutics market is expected to reach<br />
US$20.2 bn by the end of 2025. It is expanding at a CAGR of<br />
10.70% between 2015 and 2025.<br />
Elafibranor Propels Global NASH <strong>Market</strong><br />
The major segments of the market by drug type include<br />
Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and<br />
potential drug candidates in phase III. Elafibranor is expected to<br />
lead the market in the near future by being the largest and fastest<br />
growing segment of the global non-alcoholic steatohepatitis<br />
therapeutics market. Elafibranor is currently the most advanced<br />
and most effective drug in this market and is expected to exhibit<br />
the highest CAGR of all the various drug types.
Change language